Evidence map›Paper›PMID 39974348›Full record

ArticleFrontiers in cell and developmental biology2024

100% oxygen mobilizes stem cells and up-regulates MIF and APRIL in humans: a new point on the hormetic dose curve.

Kent J MacLaughlin, Gregory P Barton, Julia E MacLaughlin, Jacob J Lamers, Matthew D Marcou, Matthew J O'Brien, Rudolf K Braun, Marlowe W Eldridge

Abstract read
In one paragraph

Article in Frontiers in cell and developmental biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Trial
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Kent J MacLaughlinDepartment of Pediatrics, University of Wisconsin, Madison, WI, United States.
Gregory P BartonDepartment of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, United States.
Julia E MacLaughlinMedical Oxygen Hyperbaric Clinic, The American Center, Madison, WI, United States.
Jacob J LamersDepartment of Pediatrics, University of Wisconsin, Madison, WI, United States.
Matthew D MarcouDepartment of Pediatrics, University of Wisconsin, Madison, WI, United States.
Matthew J O'BrienUniversity of Wisconsin School of Medicine and Public Health, Madison, WI, United States.
Rudolf K BraunDepartment of Pediatrics, University of Wisconsin, Madison, WI, United States.
Marlowe W EldridgeDepartment of Pediatrics, University of Wisconsin, Madison, WI, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: The aim of the current study was to test normobaric 100% oxygen (NBO) (PiO2 = 713 mmHg) for stem cell mobilization and cytokine modulation. Although current oxygen therapy (PiO2 = 1,473-2,233 mmHg) is well known to mobilize stem cells and modulate cytokine, little is known about NBO and its place on the low dose stimulation phase of the hormetic dose curve of oxygen. We asked the question, will NBO mobilize stem cells and modulate cytokines. A positive outcome presents the potential to create and refine oxygen treatment protocols, expand access, and optimize patient outcomes. Methods: Healthy 30-35-year-old volunteers were exposed to 100% normobaric oxygen for 60 min, M-F, for 10 exposures over 2 weeks. Venous blood samples were collected at four time points: 1) prior to the first exposure (serving as the control for each subject), 2) immediately after the first exposure (to measure the acute effect), 3) immediately before the ninth exposure (to measure the chronic effect), and 4) three days after the final exposure (to assess durability). Blinded scientists used flow cytometry to gate and quantify the Stem Progenitor Cells (SPCs). Results: CD45dim/CD34+/CD133+ and CD45+/CD34+/CD133+ were significantly mobilized following nine daily one-hour exposures to normobaric 100% oxygen. Conversely CD45-/CD34+/CD133+, CD45-/CD34+/CD133- and CD45-/CD34-/CD133+ phenotypes were downregulated suggesting differentiation into more mature phenotypes. The CD133+ phenotype exhibited a maturing from CD45- to CD45dim stem cells. CD45-/CD34, CD45-/CD31 and CD45-/CD105 were downregulated with no changes in related CD45dim and CD45 Conclusion: This study demonstrates that 100% normobaric oxygen mobilizes stem cells and upregulates the expression of the inflammatory cytokines marking a new point on the low dose stimulation phase of the hormetic dose curve of oxygen.

Indexed as

A proliferation inducing ligand (APRIL)hemangioblast differentiationhematopoietic (stem cell) transplant (HSCT)inflammatory cyotokinesmacrophage migration inhibition factoroxygen therapyproangiogenicstem cell mobilization and homing

Identifiers

PMID39974348
PMCPMC11836035

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.